ArticleInternational journal of general medicine2026
Prognostic Value of MicroRNA Profiles in Septic Patients with Rare Hereditary Anemias: Insights from a Longitudinal Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNAs (miRNAs) are small molecules that regulate gene expression and may influence the severity and progression of rare hereditary anemias. Understanding their role can support the development of targeted treatments. To our knowledge, this multicenter longitudinal cohort is among the first to characterize miRNA profiles-particularly miR-155-in pediatric patients with rare hereditary anemias presenting with sepsis, and to report exploratory translational observations relevant to gene-based modulation frameworks. Objective: This study aimed to profile miRNA expression in septic patients with rare hereditary anemias and evaluate associations with disease severity, progression, and response to gene therapy. Methods: This prospective cohort study was conducted at five medical centers in the United States and Saudi Arabia, enrolling 400 participants-200 patients with rare hereditary anemias and 200 healthy controls. Blood samples were analyzed using high-throughput sequencing and advanced bioinformatics. Randomization and blinding procedures were applied to ensure data integrity and minimize bias. Results: At baseline enrollment during septic presentation, patients exhibited significantly lower mean hemoglobin levels compared to controls (9.2 g/dL vs 12.5 g/dL, p < 0.001). Patients with hereditary anemia had significantly lower average hemoglobin levels (9.2 g/dL) compared to controls (12.5 g/dL, p < 0.001) and higher reticulocyte counts. miR-155 was upregulated 2.5-fold in affected patients (p < 0.01). These patients required an average of six transfusions annually, compared to none in the control group (p < 0.001). Thirty-five percent of patients experienced worsening anemia over time. ROC curve analysis demonstrated miR-155 as a strong diagnostic biomarker, with 85% sensitivity, 90% specificity, and an AUC of 0.97. Conclusion: miR-155 plays a key role in the progression of rare hereditary anemias in septic patients and shows potential as both a diagnostic and therapeutic target. These findings highlight opportunities for personalized, miRNA-based therapies to improve disease management and patient outcomes. No clinically evident severe vector-related adverse events were observed during follow-up. Clinical Trial Number: ECRIN-EU-TRIAL-2025-002739.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.